Literature DB >> 10831642

Effects of icodextrin in automated peritoneal dialysis on blood pressure and bioelectrical impedance analysis.

G Woodrow1, B Oldroyd, G Stables, J Gibson, J H Turney, A M Brownjohn.   

Abstract

BACKGROUND: Glucose absorption from glucose-based dialysis fluids limits ultrafiltration from the daytime dwell in automated peritoneal dialysis (APD). Icodextrin may allow greater ultrafiltration during the daytime period in APD, enhancing fluid control.
METHODS: A 7.5% icodextrin dialysate was compared with a 2. 27% glucose dialysate for the daytime dwell in 14 subjects on APD. Blood pressure, weight and body water compartments estimated by multifrequency bioelectrical impedance (MFBIA) were determined in subjects using 2.27% glucose as the daytime dwell and then repeated 1 month after switching to icodextrin.
RESULTS: Icodextrin resulted in symptomatic hypotension requiring reduction of antihypertensive medication in six of the 14 patients. Despite this reduction in treatment, systolic blood pressure fell from 142.4 (23.9) mmHg to 122.9 (17.7) mmHg, P<0.005, and diastolic blood pressure tended to fall from 82.8 (9.8) mmHg to 76.8 (10.1) mmHg, P=0.075. Change in systolic blood pressure significantly correlated with changes in weight (r=0.62, P<0.05) and MFBIA estimates of total body water (TBW) (r=0.56, P<0.05), extracellular water (ECW) (r=0.79, P<0.002), extra/intracellular water ratio (ECW/ICW) (r=0.72, P<0.01) and derived resistances R(ecf) of ECW (r=-0.69, P<0.01) and R(inf) of TBW (r=-0.66, P<0.02). Changes in diastolic blood pressure significantly correlated with changes in ECW (r=0.64, P<0.02) and ECW/ICW ratio (r=0.58, P<0.05), and almost significantly with R(ecf) (r=-0.51, P=0.08) and R(inf) (r=-0.52, P=0.07) estimated by MFBIA, but not with changes in weight or TBW.
CONCLUSIONS: Use of icodextrin for the daytime dwell in APD results in improved fluid balance and blood pressure control compared with 2.27% glucose. MFBIA detected clinically important changes in fluid content in these patients.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831642     DOI: 10.1093/ndt/15.6.862

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  10 in total

1.  Icodextrin increases technique survival rate in peritoneal dialysis patients with diabetic nephropathy by improving body fluid management: a randomized controlled trial.

Authors:  Yuji Takatori; Shigeru Akagi; Hitoshi Sugiyama; Junko Inoue; Shoichiro Kojo; Hiroshi Morinaga; Kazushi Nakao; Jun Wada; Hirofumi Makino
Journal:  Clin J Am Soc Nephrol       Date:  2011-04-14       Impact factor: 8.237

2.  Solutions for peritoneal dialysis in children: recommendations by the European Pediatric Dialysis Working Group.

Authors:  Claus Peter Schmitt; Sevcan A Bakkaloglu; Günter Klaus; Cornelis Schröder; Michel Fischbach
Journal:  Pediatr Nephrol       Date:  2011-03-31       Impact factor: 3.714

Review 3.  Optimizing peritoneal dialysis prescription for volume control: the importance of varying dwell time and dwell volume.

Authors:  Michel Fischbach; Ariane Zaloszyc; Betti Schaefer; Claus Peter Schmitt
Journal:  Pediatr Nephrol       Date:  2013-08-02       Impact factor: 3.714

4.  Icodextrin produces higher ultrafiltration in diabetic than in non-diabetic patients on continuous cyclic peritoneal dialysis.

Authors:  Mufazzal Ahmad; Tarun Jeloka; Theodoros Pliakogiannis; Shruti Tapiawala; Hui Zhong; Joanne M Bargman; Dimitrios Oreopoulos
Journal:  Int Urol Nephrol       Date:  2007-11-08       Impact factor: 2.370

Review 5.  Icodextrin: a review of its use in peritoneal dialysis.

Authors:  James E Frampton; Greg L Plosker
Journal:  Drugs       Date:  2003       Impact factor: 9.546

Review 6.  Assessment and Management of Hypertension among Patients on Peritoneal Dialysis.

Authors:  Vasilios Vaios; Panagiotis I Georgianos; Vassilios Liakopoulos; Rajiv Agarwal
Journal:  Clin J Am Soc Nephrol       Date:  2018-10-19       Impact factor: 8.237

Review 7.  Icodextrin and peritoneal dialysis: advantages and new applications.

Authors:  Periklis Dousdampanis; Carlos Guido Musso; Konstantina Trigka
Journal:  Int Urol Nephrol       Date:  2017-07-03       Impact factor: 2.370

8.  Clinical effects of icodextrin in peritoneal dialysis.

Authors:  Trijntje T Cnossen; Constantijn J Konings; Frank M van der Sande; Karel M Leunissen; Jeroen P Kooman
Journal:  NDT Plus       Date:  2008-10

9.  Bimodal solutions or twice-daily icodextrin to enhance ultrafiltration in peritoneal dialysis patients.

Authors:  Periklis Dousdampanis; Konstantina Trigka; Joanne M Bargman
Journal:  Int J Nephrol       Date:  2013-01-08

10.  Benefits of a continuous ambulatory peritoneal dialysis (CAPD) technique with one icodextrin-containing and two biocompatible glucose-containing dialysates for preservation of residual renal function and biocompatibility in incident CAPD patients.

Authors:  Hye Eun Yoon; Yoon Kyung Chang; Seok Joon Shin; Bum Soon Choi; Byung Soo Kim; Cheol Whee Park; Ho Cheol Song; Sun Ae Yoon; Dong Chan Jin; Yong-Soo Kim
Journal:  J Korean Med Sci       Date:  2014-09-02       Impact factor: 2.153

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.